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ABSTRACT 74 
Cellular senescence is a cell state implicated in various physiological processes and a wide 75 
spectrum of age-related diseases.  Recently, interest in therapeutically targeting senescence to 76 
improve healthy aging and age-related disease (senotherapeutics) has been growing rapidly. 77 
Thus, the accurate detection of senescent cells, especially in vivo, is essential.  Here, we present a 78 
consensus from the International Cell Senescence Association (ICSA), defining and discussing 79 
key cellular and molecular features of senescence and offering recommendations on how to use 80 
them as biomarkers.  We also present a resource tool to facilitate the identification of genes 81 
linked with senescence (SeneQuest, available at http://Senequest.net).  Lastly, we propose an 82 
algorithm to accurately assess and quantify senescence, both in cultured cells and in vivo.    83 
 84 
85 
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MAIN TEXT 86 
Cellular senescence: walking a line between life and death  87 
 Cell states link both physiological and stress signals to tissue homeostasis and organismal 88 
health.  In both cases, the outcomes vary and are determined by the signal characteristics (type, 89 
magnitude and duration), spatiotemporal parameters (where and when) and cellular capacity to 90 
respond (Gorgoulis et al., 2018).  In the case of potentially damaging stress, damage can be 91 
reversed and cells restored structural and functional integrity.  Alternatively, damage can be 92 
irreversible and cells activate death mechanisms mainly to restrict the impact on tissue 93 
degeneration.  Between these extremes, cells can acquire other states, often associated with 94 
survival, but also with permanent structural and functional changes.  An example is the non-95 
proliferative but viable state, distinct from G0 quiescence and terminal differentiation, termed 96 
cellular senescence (Rodier and Campisi, 2011).  Formally described in 1961 by Hayflick and 97 
colleagues, cellular senescence derived from the latin word “senex” meaning “old” (Hayflick 98 
and Moorhead, 1961), was originally observed in normal diploid cells that ceased to proliferate 99 
after a finite number of divisions (Hayflick limit), later attributed to telomere shortening (see 100 
section “Cell cycle withdrawal”).   101 
 Cellular senescence has since been identified as a response to numerous stressors, 102 
including exposure to genotoxic agents, nutrient deprivation, hypoxia, mitochondrial dysfunction 103 
and oncogene activation (Table 1: Senescence inducers).  Over the last decade, improved 104 
experimental tools and the development of reporter/ablation mouse models have significantly 105 
advanced our knowledge about causes and phenotypic consequences of senescent cells.  106 
However, specific markers and a consensus definition of what constitutes senescent cells are 107 
lacking.  Further, although a link to organismal aging is clear, aging and senescence are not 108 
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synonymous (Rodier and Campisi, 2011).  Indeed, cells can undergo senescence, regardless of 109 
organismal age, due to myriad signals, including those independent of telomere shortening.  110 
Consequently, senescent cells are detected at any life stage, from embryogenesis, where they 111 
contribute to tissue development, to adulthood, where they prevent the propagation of damaged 112 
cells and contribute to tissue repair and tumor suppression.  Thus, cellular senescence might be 113 
an example of evolutionary antagonistic pleiotropy or an abortive cellular program with 114 
detrimental effects. Here, we clarify the nature of cellular senescence by: i) presenting key 115 
features of senescent cells; ii) providing a comprehensive definition of senescence, iii) 116 
suggesting means to identify senescent cells; and iv) delineating the role of senescent cells in 117 
physiological and pathological processes, that altogether/overall pave the way for developing new 118 
therapeutic strategies.   paving the way for new therapeutic strategies. 119 
 120 
Definition and characteristics of cellular senescence  121 
 Cellular senescence is a cell state triggered by stressful insults and certain physiological 122 
processes, characterized by a prolonged and generally irreversible- cell-cycle arrest with 123 
secretory features, macromolecular damage and altered metabolism (Figure 1.  These features 124 
can be inter-dependent (Figure 1) but for clarity are described here separately. 125 
Cell cycle arrest  126 
 One common feature of senescent cells is an essentially irreversible cell cycle arrest 127 
which can be an alarm-response instigated by deleterious stimuli or aberrant proliferation.  This 128 
cell cycle withdrawal differs from quiescence and terminal differentiation (He and Sharpless, 129 
2017).  Quiescence is a temporary arrest state, with proliferation re-instated by appropriate 130 
stimuli; terminal differentiation is the acquisition of specific cellular functions, accompanied by 131 
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a durable cell cycle arrest mediated by pathways distinct from those of cellular senescence 132 
(Figure 2).  In turn, senescent cells acquire a new phenotype, which can lead to an abortive 133 
differentiation program.  Although the senescence cell cycle arrest is generally irreversible, cell 134 
cycle re-entry can occur under certain circumstances, particularly in tumor cells (Galanos et al., 135 
2016; Milanovic et al., 2018; Patel et al., 2016; Saleh et al., 2019) (Figure 2).  136 
 In mammalian cells, the retinoblastoma (RB) family and p53 protein are important for 137 
establishing senescent cell cycle arrest (Rodier and Campisi, 2011).  RB1 and its family 138 
members p107 (RBL1) and p130 (RBL2) are phosphorylated by specific CDKs (CDK4, CDK6, 139 
CDK2).  This phosphorylation reduces the ability of RB family members to repress E2F-family 140 
transcription factor activity, which is required for cell cycle progression (Sharpless and Sherr, 141 
2015).  In senescent cells, however, the CDK2 inhibitor p21WAF1/Cip1 (CDKN1A) and CDK4/6 142 
inhibitor p16INK4A (CDKN2A) accumulate.  This accumulation results in persistent activation of 143 
RB-family proteins, inhibition of E2F transactivation and consequent cell cycle arrest, which, in 144 
time, cannot be reversed by subsequent inactivation of RB-family proteins or p53 (Beausejour et 145 
al., 2003).  This persistence is enforced by heterochromatinization of E2F target genes (Salama 146 
et al., 2014), the effects of cytokines secreted by senescent cells (Rodier and Campisi, 2011), 147 
and/or enduring ROS production (Takahashi et al., 2006).  Notably, in senescent murine cells, 148 
ARF, an alternate reading frame protein of the p16INK4a gene locus that activates p53, also has an 149 
important role in regulating cell cycle arrest (Sharpless and Sherr, 2015).   150 
 Additional features of the senescent cell-cycle arrest include ribosome biogenesis defects 151 
and derepression of retrotransposons (De Cecco et al., 2019; Lessard et al., 2018).  However, 152 
currently no specific marker of the senescent cell-cycle arrest has been identified (Hernandez-153 
Segura et al., 2017).  For example, RB and p53 activation also occurs in other forms of cell-cycle 154 
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arrest (Rodier and Campisi, 2011). Even p16INK4A, which is considered more specific to 155 
senescence, is expressed in certain non-senescent cells (Sharpless and Sherr, 2015), and is not 156 
expressed by all senescent cells (Hernandez-Segura et al., 2017).  Thus, detecting a senescence-157 
associated cell cycle arrest requires quantification of multiple factors/features.   158 
Secretion  159 
 Senescent cells secrete a plethora of factors, including pro-inflammatory cytokines and 160 
chemokines, growth modulators, angiogenic factors and matrix metalloproteinases (MMPs), 161 
collectively termed the Senescent Associated Secretory Phenotype (SASP or Senescence 162 
Messaging Secretome (SMS) (Figure 1, Table 2) (Coppe et al., 2010; Kuilman and Peeper, 163 
2009).  The SASP constitutes a hallmark of senescent cells and mediates many of their patho-164 
physiological effects.  For example, the SASP reinforces and spreads senescence in autocrine 165 
and paracrine fashions (Acosta et al., 2013; Coppe et al., 2010; Kuilman and Peeper, 2009), and 166 
activates immune responses that eliminate senescent cells (Krizhanovsky et al., 2008a; Munoz-167 
Espin and Serrano, 2014).  SASP factors mediate developmental senescence (Munoz-Espin et al., 168 
2013; Storer et al., 2013), wound healing (Demaria et al., 2014) and tissue plasticity (Mosteiro et 169 
al., 2016), and contribute to persistent chronic inflammation (known as inflammaging) 170 
(Franceschi and Campisi, 2014).  Thus, the SASP can explain some of the deleterious, pro-aging 171 
effects of senescent cells.  Further, the SASP can recruit immature immune-suppressive myeloid 172 
cells to prostate and liver tumors (Di Mitri et al., 2014; Eggert et al., 2016) and stimulate 173 
tumorigenesis by driving angiogenesis and metastasis (Coppe et al., 2010). 174 
 While the senescent cell cycle arrest is regulated by the p53 and p16INK4A/Rb tumor 175 
suppressor pathways, the SASP is controlled by enhancer remodeling and activation of 176 
transcription factors such as NF-κB, C/EBPβ and GATA4 (Ito et al., 2017; Kang et al., 2015; 177 
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Kuilman and Peeper, 2009; Salama et al., 2014), and mTOR (mammalian target of rapamycin) 178 
and p38MAPK signaling pathways (Freund et al., 2011; Ito et al., 2017; Kuilman and Peeper, 179 
2009).  Upstream signals triggering SASP activation are multiple, and differ depending on the 180 
senescence inducer, but include DNA damage, cytoplasmic chromatin fragments (CCFs) that 181 
trigger a type1 interferon response, and damage-associated molecular patterns (DAMPs) that 182 
activate the inflammasome (Acosta et al., 2013; Davalos et al., 2013; Li and Chen, 2018).   183 
 The SASP composition and strength varies substantially, depending on the duration of 184 
senescence, origin of the pro-senescence stimulus and cell type (Childs et al., 2015).  Further, 185 
single cell RNA-Seq reveals considerable cell-to-cell variability of SASP expression (Wiley et 186 
al., 2017b).  For example, transition from an early TGF-β-dependent to a pro-inflammatory 187 
secretome is governed by fluctuation of Notch1 activity (Ito et al., 2017).  Moreover, an 188 
interferon type I response occurs as a later event, and is driven in part by derepression of LINE-1 189 
retrotransposable elements (De Cecco et al., 2019).  Senescent cells also communicate with their 190 
microenvironment through juxtacrine NOTCH/JAG1 signalling (Ito et al., 2017), release of ROS 191 
(Kuilman et al., 2010), cytoplasmic bridges (Suppl. Video 1) (Biran et al., 2015) and 192 
extracellular vesicles, such as exosomes (Takasugi et al., 2017).  Overall, defining the senescent 193 
secretome in each biological context will help identify senescence-based molecular signatures.  194 
Macromolecular damage  195 
DNA damage  196 
 The first molecular feature associated with senescence was telomere shortening, a result 197 
of the DNA end-replication problem, during serial passages (Shay and Wright, 2019).  Telomeres 198 
are repetitive DNA structures, found in terminal loops at chromosomal ends, and stabilized by 199 
the Shelterin protein complex. This organization renders telomeres unrecognizable by the DDR 200 
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and DSB repair pathways (de Lange, 2018; Shay and Wright, 2019). Telomerase, the enzyme 201 
that maintains telomere length, is not expressed by most normal somatic (non-stem) cells, but is 202 
expressed by most cancer cells that have overcome senescence. Moreover, telomerase activity 203 
reconstitution in normal cells leads to telomere elongation, extending their replicative life-span 204 
in culture (Bodnar et al., 1998; Shay and Wright, 2019). 205 
 Telomere shortening during proliferation culminates in telomeric DNA loop 206 
destabilization and telomere uncapping, generating Telomere dysfunction-Induced Foci (TIFs) 207 
that activate the DDR, eventually causing cell-cycle arrest.  This response can also be elicited by 208 
inhibiting or altering genes involved in telomere maintenance (d'Adda di Fagagna, 2008).  209 
Another form of DNA damage, termed Telomere-Associated Foci (TAFs), can exist at telomeres 210 
due to oxidative DNA damage at telomeric G-reach repeats, irrespective of telomere length or 211 
Shelterin loss (de Lange, 2018; Shay and Wright, 2019). 212 
 Although half the persistent DNA damage foci in senescent cells localize to telomeres, 213 
other stressful subcytotoxic insults can trigger senescence by inducing irreparable DNA damage 214 
(Figure 1).  Numerous genotoxic agents, including radiation (ionizing and UV), pharmacological 215 
agents (e.g., certain chemotherapeutics), and oxidative stress trigger senescence. Moreover, 216 
activated oncogenes can induce senescence (known as OIS) as a tumor suppressive response, 217 
restricting the uncontrolled proliferation of potentially oncogenic cells.  OIS is often mediated by 218 
the tumor suppressors p16INK4A and ARF, both encoded by the CDKN2A locus, imposing a cell-219 
cycle arrest (Kuilman et al., 2010; Serrano et al., 1997).  But the DDR also plays a major role in 220 
triggering OIS (Gorgoulis and Halazonetis, 2010; Gorgoulis et al., 2018; Halazonetis et al., 221 
2008). In this case, the damage signal originates at collapsed replication forks as a result of 222 
oncogene-driven hyperproliferation.  Recently, it was shown that the DDR and ARF pathways 223 
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can act in concert during OIS with the former requiring a lower oncogenic load than the latter 224 
(Gorgoulis et al., 2018).  225 
Senescent cells harbor persistent nuclear DNA damage foci termed DNA-SCARS (DNA- 226 
segments with chromatin alterations reinforcing senescence).  DNA-SCARS are distinct from 227 
transient damage foci; unlike transient foci, they specifically associate with promyelocytic 228 
leukemian (PML) nuclear bodies, lack the DNA repair proteins RPA and RAD51 and ssDNA 229 
and contain activated forms of the DDR mediators CHK2 and p53 (Rodier et al., 2011).  DNA-230 
SCARS are dynamic structures, with the potential to regulate multiple aspects of the senescent 231 
cells, including the growth arrest and SASP (Rodier et al., 2011). However, as not all 232 
senescence-inducing stimuli generate a persistent DNA damage response, DNA-SCARS are not 233 
a global feature of the senescent cells.  CCFs are another type of DNA damage in senescent cells 234 
(Ivanov et al., 2013). These cytoplasmic chromatin fragments activate a proinflammatory 235 
response, mediated by the cGAS–cGAMP–STING pathway (Ivanov et al., 2013; Li and Chen, 236 
2018), that can serve as another non-inclusive senescence-associated marker. 237 
Protein damage 238 
 Proteotoxicity is a hallmark of aging and cellular senescence (Kaushik and Cuervo, 239 
2015).  Hence, damaged proteins help identify senescent cells (Figure 1).  A prominent source of 240 
protein damage is ROS, which oxidize both methionine and cysteine residues and alter protein 241 
folding and function (Hohn et al., 2017).  Many protein tyrosine phosphatases (PTPs) contain 242 
cysteine residues in their active sites that can be inactivated by oxidation.  This inactivation can 243 
trigger senescence by hyperactivating ERK signaling, similar to the effect of activated oncogenes 244 
(Deschenes-Simard et al., 2013).  High phospho-ERK levels were detected in pre-neoplastic 245 
lesions, rich in senescent cells, such as melanocytic nevi and benign prostatic hyperplasia (BPH) 246 
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(Deschenes-Simard et al., 2013) and are a characteristic of therapy-induced senescence 247 
(Haugstetter et al., 2010).  The PTP oxidation pattern (the oxPTPome) can be revealed by a 248 
monoclonal antibody that recognizes oxidized cysteine (Karisch et al., 2011).    249 
ROS, in the presence of metals, can carbonylate proline, threonine, lysine and arginine 250 
residues.  Protein carbonylation exposes hydrophobic surfaces, leading to unfolding and 251 
aggregation, and protein carbonyl residues can be specifically detected using antibodies 252 
(Nystrom, 2005).  Moreover, carbonyl residues can react with amino groups to form Schiff-253 
bases, contributing to protein aggregation.  Subsequent cross-linking with sugars and lipids 254 
forms insoluble aggregates, termed lipofuscin from the Greek “lipo” meaning fat and “fuscus” 255 
meaning dark.  Lipofuscin can be visualized in lysosomes by light microscopy or a histochemical 256 
method using a biotinylated Sudan Black-B analogue (GL13) (Evangelou et al., 2017).  The 257 
latter is emerging as another indicator of senescent cells in culture and in vivo (Evangelou et al., 258 
2017; Gorgoulis et al., 2018; Myrianthopoulos et al., 2019).  It should be noted that damage 259 
accumulation continues, even when cell division ceases, and can continue for months or even 260 
years.  261 
 Most protein oxidative damage is not reversible, and degradation by the ubiquitin 262 
proteasome system (UPS) or autophagy often eliminates these proteins.  As the UPS (Deschenes-263 
Simard et al., 2013)  and autophagy are active in senescent cells, they could prove to be useful in 264 
chacterizing the senescent state (Ogrodnik et al., 2019a).  Similarly, PML bodies act as sensors 265 
of reactive oxygen species and oxidative damage (Niwa-Kawakita et al., 2017) and can also be 266 
non-exclusive biomarkers of cellular senescence (Vernier et al., 2011).   267 
Lipid damage  268 
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 Lipids are essential for cell membrane integrity, energy production and signal 269 
transduction.  Some age-related diseases are characterized by altered lipid metabolism, resulting 270 
in lipid profile changes (Ademowo et al., 2017).  Although senescent cells are marked by 271 
changes in lipid metabolism, it is unclear how this contributes to the senescent phenotype (Figure 272 
1).   273 
 Mitochondrial dysfunction during senescence can result in ROS-driven lipid damage, 274 
lipid deposits (Correia-Melo et al., 2016; Ogrodnik et al., 2017) and lipofucin accumulation 275 
(Gorgoulis et al., 2018).  Apart from oxidation, lipid-derived aldehyde modifications [e.g., 4-276 
hydroxy-2-nonenal (4-HNE)] have been reported in senescent cells (Ademowo et al., 2017; Jurk 277 
et al., 2012). 278 
 Lipid accumulation in senescent cells can be visualized using various commercial dyes 279 
and assays (Ogrodnik et al., 2017) or immunostaining for lipid associated proteins such as 280 
Perilipin 2 (Ogrodnik et al., 2017).  Importantly, genetic or pharmacological clearance of 281 
senescent cells in obese and aging mice reduced lipid deposits in liver (Ogrodnik et al., 2017)  282 
and brain (Ogrodnik et al., 2019b).   283 
 Despite the association with lipid accumulation, our knowledge about specific lipid 284 
metabolite composition in senescent cells is sparse.  Fatty acids, their precursors and 285 
phospholipid catabolites, such as eicosapentaenoate (EPA), malonate, 7-alpha-hydroxy-3-oxo-4-286 
cholestenoate (7-HOCA) and 1-stearoylglycerophosphoinositol increase in senescent fibroblasts, 287 
whereas linoleate, dihomo-linoleate and 10-heptadecenoate decline (James et al., 2015).  288 
Moreover, free cholesterol rises, accompanied by reduced phospholipids and cholesteryl esters 289 
derived from acetate, while fatty acid synthase and stearoyl-CoA desaturase-1 declines (Maeda 290 
et al., 2009).  Several methods are available to detect lipid changes in tissues and cells, but their 291 
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use as a senescence biomarker remains limited due to high variability of the senescence-292 
associated lipid profile.  For example, lipid metabolites vary significantly between oncogene-293 
induced senescence and replicative senescence (Quijano et al., 2012). 294 
Deregulated metabolic profile 295 
Mitochondria 296 
 Senescent cells exhibit several changes in mitochondrial function, dynamics and 297 
morphology.  Mitochondria in senescent cells are less functional, showing decreased membrane 298 
potential, increased proton leak, reduced fusion and fission rates, increased mass and abundance 299 
of tricarboxylic acid (TCA) cycle metabolites (Kaplon et al., 2013; Passos et al., 2010).  While 300 
mitochondria are more abundant, it appears their ability to produce ATP is compromised (Birch 301 
and Passos, 2017; Korolchuk et al., 2017).  In contrast, senescent cells often produce more ROS, 302 
which can cause protein and lipid damage, as discussed in previous sections (see ‘protein 303 
damage’ and ‘lipid damage’), but also telomere shortening and DDR activation (Passos et al., 304 
2007).  Targeting aspects of mitochondrial biology, such as the electron transport chain (ETC), 305 
complex I assembly, mitochondrial fission rates and biogenesis, mitochondrial sirtuins and/or 306 
disruption of the TCA cycle can trigger senescence (Correia‐Melo et al., 2016; Jiang et al., 2013; 307 
Kaplon et al., 2013; Miwa et al., 2014; Moiseeva et al., 2009; Park et al., 2010; Wiley et al., 308 
2016).  Altered AMP:ATP and ADP:ATP ratios during senescence contribute to cell-cycle 309 
withdrawal by activating AMPK (AMP-activated protein kinase), a main sensor of energy 310 
deprivation (Birch and Passos, 2017).   311 
 Mitochondrial dysfunction during senescence is also implicated in SASP regulation.  312 
Mitophagy (mitochondrial clearance) in senescent cells appears to suppress the SASP 313 
(Correia‐ Melo et al., 2016).  Genetic or pharmacological inhibition of the ETC can induce 314 
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senescence even though cells lack expression of key pro-inflammatory SASP factors, such as IL-315 
6 and IL-8 (Wiley et al., 2016).  NAD+/NADH ratios are reduced in senescent cells (Wiley et al., 316 
2016), which could alter the activity of poly-ADP ribose polymerase (PARP) and sirtuins, both 317 
involved in activation of the SASP-regulator NF-kB (Birch and Passos, 2017).   318 
 While substantial data support a role for mitochondria in senescence in culture, less is 319 
known in vivo.  Mouse models of mitochondrial dysfunction and enhanced oxidative stress show 320 
increased senescence (Wiley et al., 2016), but a detailed characterization of mitochondrial 321 
function in senescent cells in vivo is lacking.  Because mitochondrial dysfunction characterizes 322 
other cellular processes (Eisner et al., 2018), it is not a consistent biomarker of senescence.  323 
Finally, it is not clear whether senescent cells contribute to declining mitochondrial function 324 
during aging and age-related diseases (Srivastava, 2017).  325 
Lysosomes 326 
 Secretion requires simultaneous activation of anabolic and catabolic processes (see 327 
“Secretion”) (Salama et al., 2014).  Increased catabolism provides energy and raw materials, and 328 
is favored by the lysosome, the end-degradation compartment of phagocytosis, endocytosis and 329 
autophagy (Settembre and Ballabio, 2014).  Lysosome biogenesis is transcriptionally-driven, and 330 
depends on the cellular energetic or degradative needs (Settembre and Ballabio, 2014).  331 
Intriguingly, when amino acid levels in the lysosomal lumen are high, mTOR1 is recruited and 332 
activated and vice versa (Settembre and Ballabio, 2014).  Additionally, lysosomes interact with 333 
mitochondria to preserve mitochondrial homeostasis (see “Mitochondria”) (Park et al., 2018).   334 
 Lysosomes in senescent cells increase in number and size, evident by the cytoplasmic 335 
granularity seen microscopically (Robbins et al., 1970); Figure 1, Suppl Video 1, for non-336 
senescent cells see Suppl Video 2).  The increased lysosomal number might reflect an attempt to 337 
15 
 
balance the gradual accumulation of dysfunctional lysosomes by producing more new 338 
lysosomes.  Thus, the balance between anabolism and catabolism, vital for secretion, is extended.  339 
This balance is maintained during OIS through the TOR-autophagy spatial-coupling-340 
compartment (TASCC), which coordinates the production of SASP factors (Salama et al., 2014).   341 
The elevated lysosomal content does not necessarily reflect increased activity, as the 342 
degradation stage of autophagy also declines (Park et al., 2018).  Thus, the lysosome-343 
mitochondrial axis degrades, leading to decreased mitochondrial turnover that increases ROS 344 
production.  Subsequently, ROS targets cellular structures, including lysosomes, forming a 345 
vicious feedback loop that induces more damage (Park et al., 2018).  The increased lysosomal 346 
mass has been linked to SA-β-gal activity (Hernandez-Segura et al., 2018), a senescence 347 
biomarker.  However, although the SA-β-gal is prominent in senescent cells (Dimri et al., 1995; 348 
Hernandez-Segura et al., 2018), it is neither required nor a determinant of the senescent 349 
phenotype (Hernandez-Segura et al., 2018).  From a therapeutic viewpoint, the enlarged 350 
lysosomal compartment offers an increased capacity to trap drugs that can be protonated, such as 351 
the selective CDK4/6 inhibitors palbociclib, ribociclib and abemaciclib.  This capacity reduces 352 
their effective concentration in the cytosol and nucleus, but counteracted by the slow release of 353 
the drugs from the lysosomes, thereby increasing drug exposure time (Llanos et al., 2019).  354 
Another senescence trait, related to lysosomal malfunction, is the intra-lysosomal accumulation 355 
of lipofuscin aggresomes (see “Protein damage” and “Lipid damage”, reviewed in (Gorgoulis et 356 
al., 2018).  Interestingly, lipofuscin was reported to stimulate expression of the anti-apoptotic 357 
factor Bcl-2, conferring resistance to apoptosis, another characteristic of senescent cells 358 
(McHugh and Gil, 2018).  Lysosomes in senescent cells also participate in chromatin processing 359 
(CCFs) (see “DNA damage” and “Secretion”) (Ivanov et al., 2013). 360 
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 361 
Senescence-associated (epi)-genetic and gene expression changes  362 
 The features listed above are associated with changes in gene expression, determined by 363 
transcriptional regulation of coding and non-coding RNAs, which can be exploited for 364 
senescence detection (Figure 1).  Here, we discuss such major alterations, and describe a novel 365 
database that can aid the identification of genes associated with senescence, termed SeneQuest 366 
(http://Senequest.net) [see Supplementary Information and Suppl. Table 1].   367 
Chromatin landscape 368 
 Epigenetic modifications occur during senescence, but are mostly context-dependent 369 
(Cheng et al., 2017).  For example, replicative senescence has been correlated with global loss of 370 
DNA methylation at CpG sites (Cheng et al., 2017).  In addition to the global loss of DNA 371 
methylation, cellular senescence is entails focal increases in DNA methylation at certain CpG 372 
islands (Cruickshanks et al., 2013).  Interestingly, this DNA methylation profile somewhat 373 
resembles the cancer- and aging-associated methylome patterns (Cruickshanks et al., 2013; Xie 374 
et al., 2018).  Cells undergoing OIS fail to show such alterations in DNA methylation (Xie et al., 375 
2018), reinforcing the diverse nature of epigenetic alterations during senescence.   376 
 Senescent cells also exhibit a global increase in chromatin accessibility, but the genome-377 
wide profile varies depending on the stimulus (De Cecco et al., 2013).  Individual histone 378 
modifications and variants (Cheng et al., 2017; Hernandez-Segura et al., 2018; Rai et al., 2014) 379 
demonstrate alterations during senescence.  For instance, H4K16ac is often enriched at active 380 
promoters in senescent, but not proliferating, cells (Rai et al., 2014).  Its accumulation correlates 381 
closely with histone variant H3.3, which is deposited into chromatin in a DNA replication-382 
independent manner by the HIRA/UBN1/CABIN1 and ASF1a chaperones (Rai et al., 2014).  383 
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Notably, N-terminus proteolytic cleavage of H3.3 correlates with gene repression in a different 384 
subset of genes during senescence (Ivanov et al., 2013).  Global loss of linker histone H1 is 385 
another senescence feature (Funayama et al., 2006).  Certain histone modifications are vital, such 386 
as elevated H4K20me3 and H3K9me3, which contribute to the proliferation arrest (Cheng et al., 387 
2017; Di Micco et al., 2011; Salama et al., 2014), whereas elevated H3K27ac at gene enhancers 388 
promotes a SASP (Hernandez-Segura et al., 2018).   389 
 Senescence is also associated with chromatin morphological changes.  Senescence-390 
associated heterochromatin foci (SAHF), visualized as DAPI-dense foci, are enriched in 391 
Heterochromatin Protein (HP) 1.  SAHFs derive from chromatin factors, including RB, histone 392 
variant macroH2A, high mobility group A proteins, the HIRA/UBN1/CABIN1 and ASF1a 393 
chaperones, and increased nuclear pore density (Boumendil et al., 2019; Salama et al., 2014).  394 
SAHFs were initially hypothesized to contribute to gene regulation (Salama et al., 2014).  395 
However, SAHFs were since shown to comprise largely late-replicating gene poor 396 
heterochromatic regions, even in proliferating cells, suggesting a small role in senescence-397 
associated gene expression (Salama et al., 2014).  Senescence is also correlated with global loss 398 
of linker histone H1 (Funayama et al., 2006).  Notably, SAHFs seem to be cell type- and 399 
stimulus-dependent, as they are not seen in all senescent cells (Di Micco et al., 2011; Kennedy et 400 
al., 2010; Sharpless and Sherr, 2015), rendering them useful for senescence identification, while 401 
the functional significance remains to be elucidated. 402 
 Another chromatin feature, termed senescence-associated distension of satellites (SADS), 403 
corresponds to de-compaction of (peri-)centric constitutive heterochromatin (Cruickshanks et al., 404 
2013; De Cecco et al., 2013; Swanson et al., 2013).  SADS precede SAHF formation and might 405 
be widely linked to senescence (Swanson et al., 2013).  Retrotransposable elements are another 406 
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type of constitutive heterochromatin related to senescence.  The normally-repressed LINE-1 (L1) 407 
retrotransposons are activated, stimulating the cGAS-STING pathway that elicits a type I 408 
interferon response (see ”Secretion”) (De Cecco et al., 2013).  Hence, in addition to triggering 409 
genomic instability, these elements fuel the SASP (Criscione et al., 2016).   410 
 Downregulation of lamin B1, a major component of the nuclear lamina, is another key 411 
feature of senescence (Dou et al., 2015; Freund et al., 2012; Shah et al., 2013; Shimi et al., 412 
2011).  Lamin B1 loss correlates with epigenetic profiles (Salama et al., 2014), as well as 413 
senescence-associated chromatin structures (SAHF and SADS) (Salama et al., 2014; Swanson et 414 
al., 2013).  Its reduction occurs predominantly at H3K9me3-rich regions, a process that appears 415 
to liberate H3K9me3 from the nuclear lamina promoting spatial rearrangement of H3K9me3-416 
heterochromatin to form SAHF (Salama et al., 2014).  Hi-C analysis (genome-wide mapping of 417 
chromatin contacts) in OIS revealed a reduction in local connectivity at regions enriched for 418 
H3K9me3 and lamin B1, perturbing these long-range interactions (Chandra et al., 2015).  419 
Replicative senescence, on the other hand, showed loss of long-range and gain of short-range 420 
interactions within chromosomes (Criscione et al., 2016), implying that the nature of senescence-421 
associated high-order chromatin interactions is stimulus and context-dependent (Zirkel et al., 422 
2018).  Furthermore, lamin B1 loss and reduced nuclear integrity is suggested to fuel the SASP 423 
by contributing to CCF formation (Dou et al., 2015; Ivanov et al., 2013), thereby stimulating the 424 
cGAS-STING pathway and interferon response (see “Secretion”) (Li and Chen, 2018).  425 
Autophagy-mediated CCF formation (Dou et al., 2015) together with reduced histone synthesis 426 
(O'Sullivan et al., 2010) might also lead to a global loss of core histones during senescence, 427 
affecting the chromatin landscape (Chan and Narita, 2019; Ivanov et al., 2013).  428 
Transcriptional signatures 429 
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 Several genes linked to the cell cycle arrest and SASP are frequently interrogated in 430 
combination with other biomarkers to validate the senescence phenotype or type of senescence 431 
(Figure 1).  For example, increased expression of the cyclin-dependent kinase inhibitors 432 
CDKN1A (p21WAF1/Cip1), CDKN2A (p16INK4A) and CDK2B (p15INK4B) and a subset of SASP 433 
genes, along with decreased expression of cyclins CCNA2 and CCNE2 and LMNB1 should be 434 
determined.  In addition, the transcriptome of putative senescent cells should be established, 435 
which can then be compared with the increasing number of existing senescence transcriptomes 436 
(Hernandez-Segura et al., 2018).   437 
 Whole-transcriptome studies have been instrumental in defining major signaling 438 
pathways involved in establishing senescence phenotypes, and in some cases predicting drug 439 
targets (Zhu et al., 2015).  A set of 13 genes was differentially regulated in several cell types 440 
undergoing distinct forms of senescence, including oncogene-, replicative- and DNA damage-441 
induced senescence (Hernandez-Segura et al., 2017).  More recently, a similar study, which 442 
considered only fibroblasts and endothelial cells, also attempted to define senescence-associated 443 
transcriptome signatures (Casella et al., 2019). Due to the current paucity of transcriptome data 444 
sets, and the availability of more single-cell studies that allow evaluation of intra-population 445 
variability (Wiley et al., 2017a; Zirkel et al., 2018), these gene signatures will likely change in 446 
coming years.  But ultimately a senescence gene expression signature will prove valuable for 447 
identifying senescence under many conditions in culture and in vivo. 448 
miRNAs and non-coding RNAs       449 
 Non-coding RNAs, particularly microRNAs (miRNAs), can influence the senescence 450 
program, alone or in concert.  Functional studies revealed several miRNAs that directly or 451 
indirectly modulate the abundance of key senescence effectors, including p53, p21WAF1/Cip1 and 452 
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SIRT1 (Suh, 2018).  miR-504 targets the p53 3’UTR, reducing p53 abundance and activity (Hu 453 
et al., 2010).  Also, Gld2-mediated stabilization of miR-122 enables its binding to the CBEP 454 
3’UTR, resulting in decreased p53 mRNA polyadenylation and translation (Burns et al., 2011).  455 
Conversely, miR-605 targets MDM2, triggering p53-mediated senescence (Xiao et al., 2011), 456 
and multiple miRNAs downregulate p21WAF1/Cip1, including 28 miRNAs that block OIS 457 
(Borgdorff et al., 2010).  Likewise, miR-24 suppresses p16INK4a in cells (Lal et al., 2008) and 458 
disease models, including osteoarthritis (Philipot et al., 2014).  Intricate miRNA feedback loops 459 
can modulate senescence programs.  For example, a p53/miRNA/CCNA2 pathway drives 460 
senescence independently of the p53/p21WAF1/Cip1 axis (Xu et al., 2019).  Similarly, p53-461 
dependent upregulation of miR-34a/b/c downregulates cell proliferation and survival factors 462 
(Hermeking, 2010).  Non-coding RNAs also regulate the SASP (Panda et al., 2017).  MiR-463 
146a/b, for example, increases weeks after senescence induction and dampens a proinflammatory 464 
arm of the SASP (Bhaumik et al., 2009). miRNAs also downregulate repressors of senescence, 465 
including Polycomb Group (PcG) members CBX7, EED, EZH2 and SUZ12 (miR-26b, 181a, 466 
210 and 424), leading to p16INK4a derepression and senescence initiation (Overhoff et al., 2014).  467 
Finally, the role of miRNAs in senescence extends beyond their classical functions.  For 468 
example, Argonaute 2 (AGO2) binds let-7f in the nucleus, forming a complex with RB1 (pRB), 469 
resulting in repressive chromatin at CDC2 and CDCA8 promoters (Benhamed et al., 2012).  470 
Silencing these E2F target genes is required for senescence initiation.   471 
Long non-coding RNAs (lncRNAs) (> 200 nt) can bind RNA, DNA or proteins to regulate 472 
senescence.  For example, ANRIL, a 30-40kb antisense transcript encoded by theCDKN2A 473 
locus, binds CBX7 to repress INK4b/ARF/INK4a expression (Kim et al., 2017).  Likewise, the 474 
lncRNA PANDA recruits PcG complexes, suppressing senescence-promoting genes (Kim et al., 475 
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2017), whereas silencing of GUARDIN, a p53-responsive lncRNA, causes senescence or 476 
apoptosis (Hu et al., 2018).  By contrast, following OIS induced by RAF, the lncRNA VAD 477 
preserves senescence by decreasing repressive H2A.Z deposition at INK promoters (Kim et al., 478 
2017).  Also, lncRNA UCA1 disrupts association of the RNA binding protein hnRNP A1 with 479 
p16INK4A, but not p14ARF, transcripts (Kim et al., 2017).  In addition, non-coding RNA profiling, 480 
with a focus on miRNAs, provides a senescence signature (Suh, 2018).  Intriguingly, the miRNA 481 
content of small extracellular vesicles released by senescent cells varies, evolving over time 482 
(Terlecki-Zaniewicz et al., 2018).   483 
Immune-regulation and anti-apoptotic proteins 484 
 The search for senescent protein markers started in OIS.  In addition to identifying known 485 
cell cycle regulators, these studies identified DCR2 as a common marker of senescence (Collado 486 
et al., 2005), later shown to characterize other types of senescence.  DCR2 is a decoy death 487 
receptor that protects senescent cells from immunity-mediated apoptosis, thus blocking immune 488 
surveillance of senescent cells (Sagiv et al., 2013).  Similarly, the natural killer (NK) cell 489 
activating receptor (NKG2D) ligands MICA and ULBP2 increase upon replicative, OIS and 490 
DNA damage-induced senescence (Krizhanovsky et al., 2008b; Sagiv et al., 2016).  Cell surface 491 
markers are of special interest because they should allow quantification, isolation and single cell 492 
transcriptional analysis of senescent cells extracted from tissues.  However, DCR2 and NKG2D 493 
ligands are not conserved among species, making mouse/human comparisons not possible.  494 
Recently, two additional upregulated cell surface markers, Notch1 in OIS and DPP4 in 495 
replicative and OIS, were identified (Hoare et al., 2016).  Both proteins have roles in regulating 496 
the SASP.  Furthermore, an oxidized form of membrane-bound vimentin was identified as a 497 
senescence marker, which could be used to target these cells by the adaptive immune system 498 
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(Frescas et al., 2017).  Finally, senescent cells are resistant to apoptosis, which can be mediated 499 
by increased expression of anti-apoptotic BCL-2 family members (Yosef et al., 2016).   500 
 501 
In vivo models to study cellular senescence 502 
Senescence reporter mice 503 
 Several transgenic mice were developed to estimate p16Ink4a expression in vivo or ex vivo 504 
using luciferase or fluorescent protein reporters.  Measuring luciferase activity longitudinally 505 
revealed an increase in p16INK4A expression as mice age, as well as an age-dependent increase in 506 
inter-animal variability, whereas isolation of fluorescent p16+ cells allowed phenotyping (Liu et 507 
al., 2019; Ohtani et al., 2010).  This approach allows the endogenous p16INK4A promoter to drive 508 
signals, but causes p16 hemizygosity.  Another mouse (p16-3MR) used a luciferase (rLUC), 509 
monomeric Red Fluorescent Protein (mRFP) and Herpes simplex Virus-Thymidine Kinase 510 
(HSV-TK) fusion protein driven by the p16INK4A promoter present on a bacterial artificial 511 
chromosome, integrated into the mouse genome (Demaria et al., 2014). This approach allows 512 
detection and killing of senescent cells, and does not perturb the endogenous CDKN2A locus.  513 
Finally, INK-ATTAC mice express a FKBP-Caspase 8 fusion-protein and eGFP reporter to kill 514 
and detect p16+ cells, driven from a 1.6 kB fragment of the p16INK4A promoter (Baker et al., 515 
2011; Folgueras et al., 2018).  Despite differences between these mice, they have been valuable 516 
in showing that senescent cells contribute to a wide range of age-related pathologies (Calcinotto 517 
et al., 2019).  Mice expressing luciferase and eGFP from p21WAF1/Cip1 promoter are also available 518 
(Ohtani et al., 2007). 519 
Murine models of accelerated senescence and aging 520 
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 Several progeric mouse models have been developed to mimic human progeric 521 
syndromes, including DNA repair and genome integrity deficiencies (Folgueras et al., 2018).  522 
Progeroid mice with accelerated senescence and shortened lifespans are also useful for assessing 523 
the role of cellular senescence in aging and testing senotherapeutics.  For example, the 524 
demonstration that ablation of p16INK4A expressing cells slowed age-related declines in progeroid 525 
BubR1H/H mice provided the first evidence that senescent cells are causal for certain aging 526 
phenotypes (Baker et al., 2011; Folgueras et al., 2018).  BUBR1 is important for the mitotic 527 
spindle assembly checkpoint (Guo et al., 2012).  BubR1H/H mice, which express 10% of the 528 
normal level of BUBR1, have increased aneuploidy, several progeroid features and increased 529 
expression of senescence markers in several organs (Folgueras AR et al., 2018).  Selective 530 
removal of p16INK4A+ cells from BubR1H/H-INK-ATTAC mice delays kyphosis, cataracts and 531 
muscle atrophy, but not cardiac arrhythmias and arterial wall stiffening, nor does it extend 532 
lifespan (Baker et al., 2011; Folgueras et al., 2018).   533 
 Similarly, Ercc1-/∆ progeroid mice, harboring a DNA repair defect, prematurely develop 534 
multiple morbidities associated with age, driven in part by accelerated accumulation of senescent 535 
cells in numerous tissues (Folgueras AR et al., 2018).  Ercc1-/∆ mice (Folgueras AR et al., 2018) 536 
express 5% of the normal level of the endonuclease ERCC1-XPF, important for nucleotide 537 
excision, interstrand crosslink and double-strand break repair.  These mice develop numerous 538 
age-related histopathologic lesions in virtually every tissue (Folgueras AR et al., 2018), and 539 
accumulate oxidative DNA damage faster than wild-type mice (Wang et al., 2012).  Treatment of 540 
Ercc1-/∆ mice with senolytic drugs reduces senescence markers and extends health span 541 
(Fuhrmann-Stroissnigg et al., 2017; Yousefzadeh et al., 2018; Zhu et al., 2015).  Cross-breeding 542 
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of these models with the p16INK4A reporter transgenes permits monitoring senescent cell burden 543 
longitudinally in live animals (Robinson et al., 2018; Yousefzadeh et al., 2018).   544 
 Hutchinson-Gilford Progeria Syndrome (HGPS) is a segmental or tissue-specific 545 
progeria, caused by mutations that compromise lamin A processing (Cau et al., 2014).  Mice 546 
with altered or deleted LMNA develop HGPS-like phenotypes.  They also accumulate senescent 547 
cells, as determined by SA-ß-gal staining and mRNA levels of senescence markers, in skeletal 548 
muscle and heart, consistent with sites of age-related pathology and disease (Folgueras AR et al., 549 
2018).  Similarly, in a mouse model of HGPS that recapitulates the pathogenic LMN splicing 550 
mutation, LmnaG609G/G609G mice, senescence in the liver and kidney was observed (Osorio et al., 551 
2011). However, senescent cells have not yet been shown to be causative for HGPS pathology.   552 
 A mouse model of trichothiodystrophy (TTD) (Andressoo et al., 2006), caused by a 553 
specific mutation in the Xpd gene, also indicated a role for senescent cells in premature aging.  554 
Here the role of senescence in driving aging in the XpdTTD/TTD was clearly documented by the fact 555 
that treatment with a D-retro inverso (DRI)-isoform peptide of FOXO4 able to disrupt FOXO4 556 
interaction with p53. Treatment with the FOXO4-DRI peptide reduced lethargy in XpdTTD/TTD 557 
mice and improved fur density, running wheel activity, and physical responses to stimuli (Baar et 558 
al., 2017).   559 
 Loss of Cu/Zn-superoxide dismutase (Sod1) in mice accelerates aging (Zhang et al., 560 
2017).  Sod1-/- mice show increased oxidative DNA damage, senescence (p16INK4A, p21WAF1/Cip1), 561 
SASP factors (Il1, Il6), SA-βgal+ cells and age-associated pathology in kidneys (Zhang et al., 562 
2017).  To date, senescence has not been demonstrated to drive pathology in Sod1-/- mice.   563 
 Deletion of the nfkb1 subunit of the transcription factor NF-κB induces premature ageing 564 
in mice. These mice have been shown to experience chronic, progressive low-grade 565 
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inflammation which contributes to a wide spectrum of ageing phenotypes and early mortality 566 
(however, in contrast to some of the widely used progeria mouse models these mice have a 567 
maximum lifespan of approximately 20 months). Furthermore, these mice show increased 568 
incidence of senescent cells in multiple tissues (Jurk et al., 2014). 569 
 Finally, the selective inbreeding of AKR/J mice resulted in numerous senescence-accelerated 570 
mouse (SAMP) strains including SAMP1-3 and SAMP6-11 (Takeda et al., 1997).  Although 571 
these mice have increased senescence and thus can be used for testing senotherapeutics, it 572 
remains unclear which mutant genes drive senescence in these strains.   573 
 574 
Identification of cellular senescence in vivo 575 
A simplified algorithm for detecting senescent cells in situ 576 
 In vivo, senescent cells reside in complex tissues.  Their impact on tissue function can be 577 
local or global due to the SASP (Xu et al., 2018).  To understand how senescence affects tissue 578 
function, tissue remodeling and aging, we need tools to identify senescent cells in tissues.   579 
 Single cell analyses can be performed on most tissues.  Common techniques include 580 
immunostaining, in-situ hybridization and multicolour (imaging) flow cytometry.  Even higher 581 
numbers of markers can be assessed by mass cytometry (Cytometry by Time-Of-Flight, CYTOF) 582 
(Abdelaal et al., 2019).  Although promising, limitations include loss of information about spatial 583 
associations and variable efficiency of isolation of different cell types, including senescent vs 584 
non-senescent cells. Therefore, microscopic imaging remains a preferred method for in situ 585 
senescence detection. 586 
 As mentioned, there is currently no single marker with absolute specificity for senescent 587 
cells.  Marker specificity varies, depending on cell type, tissue, organismal developmental stage, 588 
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species and other factors. However, some markers have more global/universal value/validity 589 
while others are related to specific senescence types.  Therefore, we advise a multi-marker 590 
approach, encompassing/combining broader and more specific markers for more robust detection 591 
of senescent cells in situ (Figure 3).  592 
Challenges to detect senescent cells in humans  593 
 The role of senescence in human disease is clear from cellular studies, while in vivo 594 
evidence is only now catching up (Childs et al., 2015; He and Sharpless, 2017; Munoz-Espin and 595 
Serrano, 2014).  OIS, initially described in culture, was the first type of senescence validated in 596 
humans (Serrano et al., 1997).  OIS or senescence induced by loss of a tumor suppressor was 597 
verified in vivo in human preneoplastic lesions (Collado et al., 2005; Gorgoulis and Halazonetis, 598 
2010; Kuilman and Peeper, 2009) and primary or treated neoplasias (Haugstetter et al., 2010).  599 
Later reports on the diverse activities of the senescence secretome (see “Secretion”) led to the 600 
recognition of its pro-tumorigenic properties, establishing what is now accepted as the dual role 601 
of senescence in carcinogenesis (Lee and Schmitt, 2019).  Evidence linking senescence to other 602 
common age-associated human diseases has recently emerged.  These diseases include 603 
neurodegenerative disorders, glaucoma, cataract, atherosclerosis/cardiovascular disease, 604 
diabetes, osteoarthritis, pulmonary, and renal and liver fibrosis (Childs et al., 2015; He and 605 
Sharpless, 2017; Munoz-Espin and Serrano, 2014) (Suppl Table 2).  606 
  In most studies, senescence is assessed in ex vivo cultures or fresh samples by SA-β-gal 607 
staining or indirect markers in formalin-fixed tissues (Haugstetter et al., 2010; He and Sharpless, 608 
2017; Kuilman and Peeper, 2009; Munoz-Espin and Serrano, 2014; Serrano et al., 1997).  Since 609 
SA-β-gal is not suitable for fixed tissues, analyzing senescence in human samples is challenging.  610 
The recently developed assay and reagent Sudan Black-B (SBB) interacts with lipofuscin, 611 
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another hallmark of senescent cells (Georgakopoulou et al., 2013). Lipofuscin is preserved in 612 
fixed material (Georgakopoulou et al., 2013)  and is resilient, as it was isolated from a 210,000 613 
year old human fossil (Harvati et al., 2019; Myrianthopoulos et al., 2019).  The test reagent is 614 
amenable to immunohistochemistry (Evangelou et al., 2017), and identified senescent Hodgkin 615 
and Reed-Sternberg (HRS) cells in Hodgkin lymphomas (cHL), where they predicted poor 616 
prognosis (Myrianthopoulos et al., 2019).  These cells are giant in size, have a large and 617 
occasionally multilobular nucleus (indication of an abortive cell cycle), have increased secretory 618 
activities, are embedded within an inflammatory milieu, and show a histological pattern strongly 619 
reflecting features of the senescence phenotype (Kuppers et al., 2012) (Figure 1).  Another 620 
method for identifying and quantifying senescent cells in vivo is SA-β-gal staining combined 621 
with ImageStream X analysis (Biran et al., 2017). 622 
 Despite promising results that each marker provides, no marker is completely 623 
senescence-specific (Sharpless and Sherr, 2015) (Sharpless and Sherr, 2015).  We recommend 624 
combining cytoplasmic (e.g., SA-β-gal, lipofuscin), nuclear (e.g., p16INK4A, p21WAF1/Cip1, Ki67) 625 
and context/cell type-specific markers (Childs et al., 2015)  (Figure 3).    626 
 627 
Conclusions, open questions and perspectives 628 
 From the first description of cellular senescence by Hayflick and colleagues almost 60 629 
years ago, significant progress has been made in understanding the characteristics and functions 630 
of senescent cells.  A limitation, particularly for studying biospecimens, remains the absence of 631 
specific markers.  To overcome this obstacle, we propose a multi-marker approach (Figure 3).  632 
This strategy could also be used to evaluate the efficacy of senolysis, an emerging therapeutic 633 
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approach that recently entered clinical trials for treatment of various age-related pathologies 634 
(Myrianthopoulos et al., 2019).   635 
 Conceptually, senescence can be considered a non-linear, multivariable [F(x,y)=z] 636 
function where the dependent variable (outcome) z depends on the independent variables x 637 
(stimulus) and y (environment).  The non-linear processing is dictated by dynamic genetic and 638 
epigenetic processes that can lead to reprogramming cycles until a steady-state is achieved.  At 639 
first glance, the outcomes appear to be cell cycle withdrawal and secretion of bioactive 640 
molecules.  However, recent evidence suggest that the cell cycle arrest is not always a necessary 641 
outcome, as post-mitotic cells, already unable to proliferate, can assume senescence-like 642 
features, and under certain conditions senescent cells can re-enter the cell cycle.  The SASP 643 
appears a common senescence-associated feature, but it is highly heterogeneous.  Thus, to 644 
understand the pleiotropic phenotypes of senescent cells, a shift from traditional reductionism to 645 
more systematic, multi-parametric approaches is needed.  The development of sophisticated high 646 
throughput methods and machine learning tools that can handle multi–omics data will help 647 
achieve this goal (Vougas et al., 2019). Although “old and new” have pros and cons, we can 648 
combine the best to achieve a “de profundis” analysis of senescent phenotypes.  This approach 649 
will likely unveil more specific senescence-associated signatures to address important 650 
unanswered questions: What causes and regulates the SASP?  How do genetic and epigenetic 651 
determinants interact with triggering stimuli and cellular microenvironments?  Which genomic 652 
repair systems act in different senescence scenarios?  What causes cells to evade the growth 653 
arrest, and what phenotypes do ‘escaped’ senescent cells acquire?  Answers to these and other 654 
questions will help develop specific panels of markers for each senescence subtype (step 3 in the 655 
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workflow) and guide the evolving field of senotherapy (van Deursen, 2019), achieving the best 656 
outcome within the spirit of precision medicine. 657 
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FIGURE LEGENDS 670 
Figure 1. The hallmarks of the senescence phenotype. Senescent cells exhibit four inter-671 
dependent (shown by the dashed thin outer cycle and bidirectional arrows) hallmarks: 1) cell 672 
cycle withdrawal, 2) macromolecular damage, 3) Secretory Phenotype (SASP) and 4) 673 
deregulated metabolism, as depicted in the outer circle (see text). The inner cycle includes 674 
distinct morphological and functional features that reflect the proposed hallmarks. Several of 675 
these traits are strongly evident in the malignant entity, the classical Hodgkin Lymphoma (see 676 
section 5). Multilobular nuclei commonly present in (senescent) HRS cells, as a result of S/M 677 
phase dissociation, are linked to cell cycle withdrawal (p21WAF1/Cip1 immunopositivity-left 678 
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image) while the inflammatory milieu is associated with SASP. Lipofouscin accumulation 679 
assessed with GL13 staining (brown cytoplasmic staining-right image) reflects macromolecular 680 
damage conferring to increased granularity (left centered image). The latter is also linked to 681 
deregulated metabolism.  Altered/increased gene expression (right centered image) that is also 682 
accompanied by increased transcriptional “noise” also confers to macromolecular damage 683 
(Ogrodnik et al., 2019). 684 
Figure 2. Cell cycle withdrawal in senescent, quiescent and terminally differentiated cells.  685 
Depicted are differences in cell cycle arrest reversibility, activated signals (see text), secretory 686 
functions and macromolecular damage that allow discrimination between these cellular states.  687 
Macromolecular damage is a common feature of senescence.  Secretion is another common 688 
feature of senescence and is sometimes (context-dependently) found in the differentiated state.  689 
Cell cycle arrest is generally considered irreversible during senescence and terminal 690 
differentiation, although cell cycle re-entry can occur under certain conditions.  Green color: 691 
active/present, red color: inactive/absent. Double-headed arrows: solid=established connection, 692 
hatched: uncertain.   693 
Figure 3. A multi-marker, three-step workflow for detecting senescent cells.  The first step 694 
of the proposed workflow includes assessing senescence-associated beta-galactosidasde (SA-β-695 
gal) activity and/or lipofuscin accumulation (SBB or GL13 staining).  Secondly, co-staining with 696 
other markers frequently observed in (p16INK4A, p21WAF1/Cip1) or absent from (proliferation 697 
markers, Lamin B1) senescent cells.  In the third step, identification of factors anticipated to be 698 
altered in specific senescence contexts should be identified.  This multi-marker workflow can 699 
lead to the recognition of senescent cells with the highest accuracy. 700 
701 
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